An Open-label Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults.
Latest Information Update: 28 Apr 2026
At a glance
- Drugs AZD 4954 (Primary) ; Laroprovstat (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Dyslipidaemias; Hyperlipoproteinaemia type II
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 22 Apr 2026 Status changed from not yet recruiting to recruiting.
- 10 Apr 2026 New trial record